{"a":[{"_":"Novartis, Bristol Myers halt autoimmune CAR-T trials due to adverse events","$":{"href":"/biotech/novartis-bristol-myers-squibb-halt-car-t-cell-trials-due-immune-events","hreflang":"en"}}]}
Trial StartnegativeCAR-TNegative
AI Analysis
Summary
Novartis and Bristol Myers Squibb have halted multiple CAR-T cell trials in autoimmune diseases due to immune-related adverse events, marking a significant setback for the therapeutic approach in this indication.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
Trials halted due to immune-related adverse events
Importance:8/10
Sentiment:
-0.80
CAR-Tautoimmuneadverse eventstrial haltsafety
Read the original article
Published by FierceBiotech on August 31, 2026 4:20 PM